RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance
RSM01 showed broad neutralizing activity against circulating LMIC RSV strains. Authors found a high barrier to resistance, supporting RSM01 as an alternative should resistance emerge with widespread use of current licensed anti-RSV mAbs.